System for Determining Ideal Drug Doses for ADHD

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

46 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-01-31

Study Completion Date

2019-09-11

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this study is to create a formal, quantitative methodology to determine what is the most beneficial dose of Central Nervous System (CNS) stimulant (Ritalin, methylphenidate) to improve cognitive and behavioral function of children diagnosed with Attention Deficit Hyperactivity Disorder (ADHD) individually. If successful, it will change the way in which the dose of CNS stimulant for treating ADHD is determined for children in need of therapeutic intervention. The project will be focused on developing the necessary methodology to analyze the children's data with the drift-decision model (DDM), and to develop the required technology, i.e., a computer game with which to measure cognitive/behavioral function and its validation with eye-tracking measurements.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Stimulant Versus Nonstimulant Medication for Attention Deficit Hyperactivity Disorder in Children

NCT00183391

Attention Deficit Disorder With Hyperactivity

COMPLETED PHASE4

The Effect of Methylphenidate Treatment in Familial Attention Deficit/Hyperactivity Disorder (ADHD)

NCT01554046

Attention Deficit/Hyperactivity Disorder Combined Type ADHD Predominantly Inattentive Type ADHD Predominantly Hyperactivity Type +1 more

COMPLETED NA

Behavioral Treatment, Drug Treatment, and Combined Treatment for Attention Deficit Hyperactivity Disorder (ADHD)

NCT00050622

Attention Deficit Disorder With Hyperactivity

COMPLETED NA

ERP Based Single-dose Predictions of Stimulants

NCT02695355

Attention Deficit Hyperactivity Disorder

COMPLETED PHASE2

Effects of Evening Dose of Immediate Release Methylphenidate on Sleep in Children With ADHD

NCT02638168

Attention Deficit Disorder With Hyperactivity Behavioral Insomnia of Childhood

TERMINATED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Attention Deficit Hyperactivity Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control

healthy children without ADHD or other mental health issues

no intervention. measure eye movement data

Intervention Type OTHER

ADHD

children diagnosed with ADHD

no intervention. measure eye movement data

Intervention Type OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

no intervention. measure eye movement data

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 8-12 years of age;
* Accompanied by caregiver (parent or legal guardian);
* Able to understand and speak English;
* Able to read basic English;
* No counseling or current/past history of psychiatric illness, as confirmed by the Child Behavior Checklist (CBCL) and Conner's rating scale

Exclusion Criteria

* Active psychosis or suicidality
* History of primary psychotic disorder (e.g., schizophrenia) or bipolar disorder
* Recent (past 2 weeks) substance abuse or dependence
* History of brain damage or significant developmental delay
* Unstable medical condition such as newly diagnosed Type I Diabetes or Rheumatoid arthritis
* Use of oral steroids
* Participation in the last 30 days in a clinical study involving an investigational drug
* Current use of a psychotropic medicine

Minimum Eligible Age

8 Years

Maximum Eligible Age

12 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes